111 Reports 9.5% Increase in Revenue for Third Quarter of Fiscal Year 2023

☀️Earnings Overview

111 ($NASDAQ:YI): The company reported total revenue of CNY 3665.2 million on September 30 2023, indicating a 9.5% year-on-year rise, for the third quarter of fiscal year 2023. Additionally, the net income for the period was CNY -93.3 million, a slight improvement from the prior year’s figure of -96.8 million.

Analysis

GoodWhale have conducted an analysis of 111‘s financials and the Star Chart reveals that 111 has a low health score of 3/10 with regard to its cashflows and debt, which means that it is less likely to sustain future operations in times of crisis. GoodWhale’s classification of 111 as a ‘cheetah’ company implies that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. 111 is strong in terms of growth, but weak in terms of dividend, profitability and asset. Given the higher risk profile associated with 111, investors with a higher risk appetite may be interested, such as venture capitalists, private equity firms or angel investors. These investors may be attracted to 111’s potential for high returns, despite the higher risk associated with such an investment. Alternatively, those who are looking for more stable investments may consider 111 to be too risky and opt for other opportunities. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for 111. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for 111. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for 111. More…

Key Ratios Snapshot

Some of the financial key ratios for 111 are shown below. More…

Peers

The company has a strong presence in the Chinese healthcare market and competes with other leading players such as China Jo-Jo Drugstores Inc, Health Advance Inc and Zur Rose Group AG. These companies are all well established providers of healthcare services, offering their respective customers a variety of products and services to choose from.

– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)

China Jo-Jo Drugstores Inc is a leading Chinese national retail drugstore chain that was founded in 2002. It is one of the largest retail drugstore chains in China, with more than 2,000 stores and sales outlets in over 200 cities across the country. As of 2022, the company has a market capitalization of 33.72M. Its Return on Equity (ROE) stands at -4.61%, indicating that the company is not generating a positive return on its shareholders’ investments. Despite this, China Jo-Jo Drugstores Inc’s strong presence in the Chinese market and its aggressive expansion plans make it an attractive investment option.

– Health Advance Inc ($OTCPK:HADV)

Health Advance Inc is a healthcare provider specializing in providing comprehensive and quality care to its patients. The company’s market capitalization stands at 984.94k as of 2022, which reflects its growth and stability in the industry. Its Return on Equity (ROE) of 57.91% is indicative of the company’s efficient use of its assets and capital to generate profits. Health Advance Inc’s impressive market cap and ROE are a testament to its continued success in providing quality care to its patients.

– Zur Rose Group AG ($LTS:0RRB)

Zur Rose Group AG is a Swiss e-commerce and mail-order pharmacy, providing customers with prescription and non-prescription medications, health and beauty products, and medical products. As of 2022, the company has a market capitalization of 357.78 million Swiss francs, indicating its value on the stock market. Furthermore, Zur Rose Group AG has a negative return on equity (ROE) of -29.55%, which is below average, indicating that the company’s management is not efficiently utilizing its shareholders’ equity to generate profits.

Summary

Investors reacted negatively to the financial report of the company on September 30 2023, with the stock price dropping on the same day. Total revenue rose 9.5% compared to the same period last year but net income decreased, from -96.8 million to -93.3 million. This suggests that the company might have difficulty growing its bottom line, even with increased revenue. Despite this, investors may want to keep an eye on the company as it could still deliver strong returns over the long term.